|
Stan Chamberlain, Ph.D. has served as Vice President of Chemistry since late 2007. Prior to coming to Inhibitex, he was Senior Group Manager in Medicinal Chemistry Oncology at Glaxo Smith Kline in Research Triangle Park, NC from 2001 to 2007, working in the area of protein kinase inhibitors. From 1995 to 2001, Dr. Chamberlain was a Group Leader in Medicinal Chemistry at Glaxo Wellcome in RTP, working in the areas of antiviral and anti-inflammatory chemotherapy. From 1986 to 1995, he held several Senior Scientist positions in the Experimental Therapy Department at Burroughs Wellcome in RTP, focusing on nucleoside agents for anti-viral and oncology applications. Dr. Chamberlain received a B.S. and a Ph.D. from the University of Iowa Chemistry Department. Dr. Chamberlain's publications and patents cover the areas of antiviral, anti-cancer and anti-inflammation chemotherapy, with a focus on protein kinase inhibitors and nucleoside derivatives. | 